Skip to main content
. Author manuscript; available in PMC: 2009 Sep 1.
Published in final edited form as: Otol Neurotol. 2008 Sep;29(6):846–853. doi: 10.1097/MAO.0b013e31817f7398

Figure 2.

Figure 2

Trastuzumab inhibits cell proliferation in vestibular schwannoma (VS) xenografts. A and B. Nude mice bearing VS xenografts were treated with saline (A, control) or trastuzumab (B) for 2 weeks. The animals received daily injections of BrdU to allow identification of proliferating cells. Representative images of xenograft frozen sections immunolabeled with anti-BrdU and anti-S100 antibodies with Alexa 568 (red, BrdU-positive) and Alexa 488 (green, S100-positive) conjugated secondary antibodies respectively are shown. Nuclei were labeled with Hoechst (blue). Arrows indicate TUNEL-positive nuclei. Scale bar=50 μm. C. The average number of BrdU-positive, S100-positive nuclei was determined for each condition from 5 random selected fields from 3-4 sections/xenograft from 2 separate animals for each group. Trastuzumab significantly reduced BrdU uptake in these xenografts (p<0.01, Student’s two-tailed t-test). Error bars represent standard error. n=total number of VS cells scored for each condition. N=total number of xenografts analyzed for each condition.